Sernova

Call Directions Website Contact the business

Sernova Sernova is a clinical-stage regenerative medicine theraupeutics company

Sernova is a clinical-stage biotechnology company that is advancing its implantable Cell Pouch™ bio-hybrid organ which works to restore the body’s normal function so that people with type 1 diabetes (T1D) and other chronic diseases can focus on what matters most: living their lives.

2026-11-06

Retrievability is an important factor in the advancement of cell replacement for ( ). ​

In a completed clinical trial, our Cell Pouch demonstrated that it supports the long-term survival and function of therapeutic cells inside the body and can be safely removed if needed.​

Learn more about our platforms' capabilities: https://bit.ly/4yX3neN

2026-11-04

Did you know that 2.1 million people are estimated to be living with diagnosed type 1 diabetes (T1D) nationwide?

November is Diabetes Awareness Month. It serves as an opportunity to recognize the individuals and families navigating the daily realities of T1D, as well as the healthcare providers who help them manage the disease.

Every person living with T1D deserves access to better treatment options and continued progress in care. Through our work, we are committed to advancing potential new treatment options with the goal of addressing the underlying loss of insulin-producing cells and ultimately achieving a functional cure.

To learn more about T1D, visit the Beyond Type 1 website: https://bit.ly/4AbtjEs

2026-10-28

Living with ( ) means navigating lifelong insulin therapy, continuous blood glucose monitoring, and daily decisions around meals, activities and rest.​

Despite advances in treatment, managing T1D still requires strict dosing schedules, ongoing monitoring and constant vigilance to help regulate blood glucose levels. As research progresses, approaches that address the underlying loss of insulin-producing beta cells remain an important area of focus.​

Learn more about T1D and our approach: https://bit.ly/4yX3neN

Our CEO, Jonathan Rigby, and Will Rust, Ph.D., CEO of Seraxis, recently joined Erin Poché of T1D Strong to discuss how o...
2026-10-26

Our CEO, Jonathan Rigby, and Will Rust, Ph.D., CEO of Seraxis, recently joined Erin Poché of T1D Strong to discuss how our proposed merger to form BetaNova Biotherapeutics will aim to advance a new era of ( ) treatment.​

By combining Seraxis’ stem cell-derived pancreatic islets and in-house cGMP manufacturing capabilities with Sernova’s clinically validated Cell Pouch Bio-hybrid Organ, the proposed company aims to address key challenges in islet cell replacement and advance a differentiated approach to T1D treatment.​
​

Read the article here: https://bit.ly/3WMLBNC

Type 1 diabetes (T1D) affects every hour of every day. Insulin injections, CGMs, and pumps address only part of what a h...
2026-10-23

Type 1 diabetes (T1D) affects every hour of every day. Insulin injections, CGMs, and pumps address only part of what a healthy pancreas does.

On a recent episode of Diabetes Connections, host Stacey Simms spoke with Jonathan Rigby, our President and CEO, and Will Rust, President and CEO of Seraxis, about our proposed merger to form BetaNova Biotherapeutics and advance a new approach to T1D cell replacement. Topics covered include:

🔬 Scaling and manufacturing stem cell-derived pancreatic islet cells

✔️ Combining stem cell-derived insulin-producing islet cells with a biohybrid organ that naturally vascularizes with surrounding tissues while remaining fully retrievable

🧬 Approaches for overcoming immunosuppression for T1D cell therapies

Listen to the podcast here: https://bit.ly/4zP56Ue

2026-10-19

Patricia Beaston, MD, PhD, has joined Seraxis as Chief Medical Officer.

Upon completion of our proposed merger with Seraxis, she will become Chief Medical Officer of the combined company, BetaNova Biotherapeutics.

Dr. Beaston has 24 years of FDA leadership experience. She served across three of the FDA’s principal centers: Center for Drug Evaluation and Research (CDER), where she evaluated endocrine therapeutics; Center for Devices and Radiological Health (CDRH); and most recently Center for Biologics Evaluation and Research (CBER), where her review responsibilities included islet cell transplantation, immune modulation in type 1 diabetes (T1D), and cell and gene therapies.

Her expertise will strengthen clinical and regulatory leadership for BetaNova as SR-02, investigational pancreatic stem cell-derived insulin-producing islets, are advanced into a Phase 1/2 clinical trial. The first patient dosing for the trial is targeted for Q1 2027.

Together, Sernova and Seraxis will aim to bring together complementary science, technology, and expertise to advance new treatment options for people living with T1D.

Read the full announcement for more details: https://sernova.com/press_releases/seraxis-and-sernova-announce-appointment-of-former-fda-medical-officer-dr-patricia-beaston-as-chief-medical-officer-of-seraxis-and-post-merger-betanova-biotherapeutics/

Check out the most recent episode of Cell & Gene: The Podcast featuring our President and CEO, Jonathan Rigby, and Serax...
2026-10-13

Check out the most recent episode of Cell & Gene: The Podcast featuring our President and CEO, Jonathan Rigby, and Seraxis President and CEO, Will Rust, PhD. With host Erin Harris, they discuss what it will take to move closer to a functional cure for type 1 diabetes, and why Sernova and Seraxis have proposed a merger to form BetaNova Biotherapeutics.

The conversation covers why Sernova’s retrievable Cell Pouch in combination with Seraxis’ stem cell-derived islets is a natural fit, the challenge of manufacturing islet cells at scale, and our planned approach to reducing the need for immune suppression. Jonathan, who has lived with T1D since age 18, also shares why this mission is personal for our team.

Watch the full episode: https://bit.ly/4z5gLhP

Jonathan Rigby, President and CEO of Sernova, recently joined Ginger Vieira for an episode of the Diabetes Nerd Podcast....
2026-10-08

Jonathan Rigby, President and CEO of Sernova, recently joined Ginger Vieira for an episode of the Diabetes Nerd Podcast. Topics covered during their discussion include:

➡️ Why insulin, CGMs, and pumps address only part of what a healthy pancreas does

➡️ How the Sernova Cell Pouch is designed to naturally vascularize with surrounding tissues for the long-term survival and function of cells, with complete retrievability

➡️ What our planned merger with Seraxis could mean for manufacturing and supplying stem cell-derived pancreatic islet cells

➡️ How we’re approaching a reduction in immune suppression over time, including next-generation gene-edited cells

➡️ Jonathan’s lived experience with type 1 diabetes, which informs the urgency of our mission to advance a potential function cure

Watch the full conversation on YouTube: https://bit.ly/3Vysp5P

2026-10-05

In connection with the recently proposed merger of Sernova and Seraxis, a financing round of $11.2 million has been closed.

The funds will be used to support cGMP manufacturing of SR-02, Seraxis’ lead stem cell-derived pancreatic islet cell program, and first patient dosing of SR-02 in the Phase 1/2 trial in Q1 2027 under an FDA-cleared IND with initial clinical data anticipated in H1 2027.

Read more about the additional plans for the new funding in our press release: https://bit.ly/4hDZEgN

Join us today at 1:30 p.m. ET as we present at NOBLE Capital Markets’ Emerging Growth Virtual Equity Conference to highl...
2026-10-01

Join us today at 1:30 p.m. ET as we present at NOBLE Capital Markets’ Emerging Growth Virtual Equity Conference to highlight the details and strategy of our proposed merger agreement with Seraxis.

Jonathan Rigby, President and CEO of Sernova and William L. Rust, Ph.D., President and CEO of Seraxis will participate in a joint presentation and fireside-style Q&A. Together they will highlight the synergies of combining investigational technologies such as Sernova’s Cell Pouch Bio-hybrid Organ with Seraxis’ stem cell-derived pancreatic islet cell programs and in-house cGMP manufacturing capabilities in pursuit of a potential functional cure for ( ) islet cell replacement.

Tune in here: https://bit.ly/3TWDEo6

Address

Sernova Biotherapeutics 700 Collip Circle, Ste 114
London, ON
N6G4X8

Alerts

Be the first to know and let us send you an email when Sernova posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Sernova:

Shortcuts

Share

Nearby businesses